Whether those effects survive the scrutiny of trials like TAG-MS, the ongoing Parkinsons studies, and the next wave of Alzheimers prevention work will determine whether the brain-volume question becomes a clinical recommendation or remains a tantalizing observational signal
The FDA has at times raised concerns about compounding of GH-related peptides, and the regulatory landscape continues to evolve
Often, these byproducts are free radicals
In a post hoc analysis of SUSTAIN 6, including 3297 subjects with type 2 diabetes and high CV risk, once-weekly semaglutide reduced the risk of MACE and each MACE component in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile, as compared with placebo [16]
Researchers have already documented the benefits of GLP-1s beyond weight loss, and the list is growing